Cargando…
DDRE-29. DE NOVO PYRIMIDINE SYNTHESIS IS A TARGETABLE VULNERABILITY IN IDH-MUTANT GLIOMA
70–90% of lower-grade gliomas and secondary glioblastomas harbor gain-of-function mutations in isocitrate dehydrogenase 1 (IDH1), causing overproduction of the oncometabolite (R)-2-hydroxyglutarate [(R)-2HG]. Although inhibitors of mutant IDH enzymes are effective in other cancers, including leukemi...
Autores principales: | Shi, Diana D, Wang, Adam C, Levitt, Michael M, Endress, Jennifer E, Xu, Min, Gao, Wenhua, Khanal, Januka, Bonal, Dennis, Kornblum, Harley I, Nguyen, Quang-De, Gradl, Stefan, Sutter, Andreas, Jeffers, Michael, Janzer, Andreas, Cahill, Daniel P, Ligon, Keith L, Abdullah, Kalil G, Harris, Isaac S, Kaelin, William G, McBrayer, Samuel K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992238/ http://dx.doi.org/10.1093/noajnl/vdab024.051 |
Ejemplares similares
-
De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma
por: Shi, Diana D., et al.
Publicado: (2022) -
Protocol to establish a genetically engineered mouse model of IDH1-mutant astrocytoma
por: Shi, Diana D., et al.
Publicado: (2023) -
DDRE-12. HETEROGENOUS RESPONSE OF IDH-MUTANT AND IDH-WT GLIOMA TO NAMPT INHIBITION
por: Rahman, Masum, et al.
Publicado: (2021) -
DDRE-32. THERAPEUTIC TARGETING OF A NOVEL METABOLIC ADDICTION IN DIFFUSE MIDLINE GLIOMA
por: Pal, Sharmistha, et al.
Publicado: (2021) -
DDRE-20. TARGETING SPHINGOLIPID PATHWAY REVEALS VULNERABILITY IN IDH1(MUT) GLIOMA
por: Dowdy, Tyrone, et al.
Publicado: (2021)